Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
| Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
| Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
| Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
| Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | ||
| Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
| Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete |
Last Updated : May 19, 2024